1. Home
  2. TXG vs MIRM Comparison

TXG vs MIRM Comparison

Compare TXG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

HOLD

Current Price

$76.56

Market Cap

8.5B

Sector

Industrials

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

BUY

Current Price

$81.45

Market Cap

7.2B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
TXG
MIRM
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
7.2B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
TXG
MIRM
Price
$76.56
$81.45
Analyst Decision
Buy
Strong Buy
Analyst Count
19
14
Target Price
$67.47
★ $145.79
AVG Volume (30 Days)
★ 3.7M
695.4K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 76.97
74.59
EPS
★ N/A
N/A
Revenue
★ $245,893,000.00
$19,138,000.00
Revenue This Year
N/A
$33.62
Revenue Next Year
$9.72
$17.65
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 68.06
N/A
52 Week Low
$11.17
$63.23
52 Week High
$102.81
$130.00

Technical Indicators

Market Signals
Indicator
TXG
MIRM
Relative Strength Index (RSI) 49.13 30.13
Support Level $74.60 $73.82
Resistance Level N/A $104.56
Average True Range (ATR) 7.16 3.80
MACD -1.48 -0.75
Stochastic Oscillator 15.28 19.04

Price Performance

Historical Comparison
TXG
MIRM

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: